Article
Garsorasib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 2 trial.
The Lancet. Respiratory medicine - 1 Aug 2024
Li Ziming, Dang Xiaomin, Huang Dingzhi, Jin Shi, Li Weiwei, Shi Jianhua, Wang Xicheng, Zhang Yiping, Song Zhengbo, Zhang Junping, Zhuang Wu, Liu Xuewen, Jiang Liyan, Meng Xiangjiao, Zhao Mingfang, Zhou Jianying, Zhang Liangming, Wang Pingli, Luo Hui, Yang Junquan, Cang Shundong, Wang Xiang, Zhang Ling, Lu Shun
Abstract excerpt
BACKGROUND: Garsorasib (D-1553; InventisBio, Shangai, China), a potent KRASG12C inhibitor, has shown promising antitumour activity in patients with KRASG12C-mutated (ie, Gly12Cys) non-small-cell lung cancer (NSCLC) in a phase 1 study. We report results from a phase 2 study conducted to evaluate the efficacy and safety of garsorasib in patients with locally advanced or metastatic KRASG12C-mutated NSCLC. METHODS:...
Topics
Join the communities discussing this publication.